5 news items
Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
VSTM
24 May 24
. Approximately 6,000-8,000 women in the U.S. and 80,000 worldwide are living with this disease. LGSOC affects younger women with bimodal peaks of diagnosis at ages
Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
VSTM
9 May 24
presentations at the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women's Cancer on March 16-18 in San Diego. These presentations included
Verastem Oncology Announces Multiple Oral Presentations At Society Of Gynecologic Oncology 2024 Annual Meeting On Women's Cancer
VSTM
11 Mar 24
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women's Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
VSTM
11 Mar 24
), at the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women's Cancer, to be held on March 16-18 in San Diego, California. Verastem
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
VSTM
5 Mar 24
is a highly recurrent, chemotherapy-resistant cancer, associated with slow tumor growth and high mortality rate. An estimated 6,000 women in the U.S. and 80,000
- Prev
- 1
- Next